Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 9(12): e114524, 2014.
Article in English | MEDLINE | ID: mdl-25474412

ABSTRACT

RATIONALE: The chemokine interleukin-8 is implicated in the development of bronchopulmonary dysplasia in preterm infants. The 77-amino acid isoform of interleukin-8 (interleukin-877) is a less potent chemoattractant than other shorter isoforms. Although interleukin-877 is abundant in the preterm circulation, its regulation in the preterm lung is unknown. OBJECTIVES: To study expression and processing of pulmonary interleukin-877 in preterm infants who did and did not develop bronchopulmonary dysplasia. METHODS: Total interleukin-8 and interleukin-877 were measured in bronchoalveolar lavage fluid from preterm infants by immunoassay. Neutrophil serine proteases were used to assess processing. Neutrophil chemotaxis assays and degranulation of neutrophil matrix metalloproteinase-9 were used to assess interleukin-8 function. MAIN RESULTS: Peak total interleukin-8 and interleukin-877 concentrations were increased in infants who developed bronchopulmonary dysplasia compared to those who did not. Shorter forms of interleukin-8 predominated in the preterm lung (96.3% No-bronchopulmonary dysplasia vs 97.1% bronchopulmonary dysplasia, p>0.05). Preterm bronchoalveolar lavage fluid significantly converted exogenously added interleukin-877 to shorter isoforms (p<0.001). Conversion was greater in bronchopulmonary dysplasia infants (p<0.05). This conversion was inhibited by α-1 antitrypsin and antithrombin III (p<0.01). Purified neutrophil serine proteases efficiently converted interleukin-877 to shorter isoforms in a time- and dose-dependent fashion; shorter interleukin-8 isoforms were primarily responsible for neutrophil chemotaxis (p<0.001). Conversion by proteinase-3 resulted in significantly increased interleukin-8 activity in vitro (p<0.01). CONCLUSIONS: Shorter, potent, isoforms interleukin-8 predominate in the preterm lung, and are increased in infants developing bronchopulmonary dysplasia, due to conversion of interleukin-877 by neutrophil serine proteases and thrombin. Processing of interleukin-8 provides an attractive therapeutic target to prevent development of bronchopulmonary dysplasia.


Subject(s)
Bronchopulmonary Dysplasia/metabolism , Interleukin-8/blood , Interleukin-8/metabolism , Respiration, Artificial/adverse effects , Serine Proteases/metabolism , Bronchopulmonary Dysplasia/enzymology , Bronchopulmonary Dysplasia/etiology , Cells, Cultured , Chemotaxis , Humans , Infant , Infant, Newborn , Infant, Premature , Neutrophils/physiology
2.
J Immunotoxicol ; 6(4): 235-42, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19908942

ABSTRACT

In the preliminary study reported here, 37 patients with breast cancer and 10 healthy volunteers were analyzed for soluble TNF-R p55 and two variants of IL-8 consisting of 72 and 77 amino acid residues (IL-8(72) and IL-8(77), respectively) in their blood and urine with novel ELISA test systems. The clinical/prognostic values of determining these inflammatory cytokines at different stages of the cancer process appeared to depend on the treatment course being evaluated. In contrast to expectations, it was noted that there was a stabile tendency for decreased TNF-R p55 and IL-8(72) levels in the plasma and urine of breast cancer patients as compared with levels observed with healthy controls. Moreover, patients that underwent polychemotherapy treatments were notable for significant decreases in IL-8(72) and TNF-R p55 levels in their blood plasma; these findings contrasted with significant increases in these parameters in these patients' urine. Interestingly, the IL-8(77) isoform that now appeared both in the urine and plasma of patients was not detectable before initiation of the polychemotherapy. In spite of all these findings, individual fluctuations among these parameters still do not allow us to establish, at this time, any strong correlations between these values with any particular breast cancer stage or a type of treatment. Nonetheless, while the results here are preliminary, they demonstrate that testing for TNF-R, along with IL-8 isoforms, in the blood plasma and urine could potentially present a valid means for monitoring of the overall immune and disease progress/remission status in breast cancer patients. Ongoing studies with larger patient sample sizes, as well as collecting and analyzing samples at multiple time points--to minimize the potential influence of any inherent variability in cytokine levels in humans--will hopefully allow us to specify what these preliminary results reported here suggest, i.e., the potential utility of this experimental approach for determining disease progression or efficacy of treatment in cancer patients.


Subject(s)
Breast Neoplasms/blood , Breast Neoplasms/urine , Interleukin-8/blood , Interleukin-8/urine , Receptors, Tumor Necrosis Factor, Type I/blood , Receptors, Tumor Necrosis Factor, Type I/urine , Tumor Necrosis Factor Decoy Receptors/blood , Tumor Necrosis Factor Decoy Receptors/urine , Adult , Aged , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Female , Humans , Middle Aged , Neoplasm Staging , Protein Isoforms , Urinalysis
3.
Cytokine ; 46(1): 12-6, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19232500

ABSTRACT

Interleukin-8 (IL-8/CXCL8) is widely expressed in fetal tissues although inflammatory changes are not seen. Circulating IL-8 is comprised of an endothelial-derived [ala-IL-8](77) isoform and another, more potent [ser-IL-8](72) secreted by most other cells; [ala-IL-8](77) can be converted into [ser-IL-8](72) by proteolytic removal of an N-terminal pentapeptide from [ala-IL-8](77). In this study, we show [ala-IL-8](77) is the predominant circulating isoform of IL-8 in premature neonates but not in term neonates/adults, who have [ser-IL-8](72) as the major isoform. This isoform switch from the less potent [ala-IL-8](77) to [ser-IL-8](72) correlates with a maturational increase in the neutrophil chemotactic potency of plasma IL-8. The emergence of [ser-IL-8](72) as the major isoform is likely due to increased plasma [ala-IL-8](77)-convertase activity and/or changes in the cellular sources of IL-8. Developmental changes in IL-8 isoforms may serve to minimize its inflammatory effects in the fetus and also provide a mechanism to restore its full activity after birth.


Subject(s)
Gene Expression Regulation, Developmental , Interleukin-8/chemistry , Interleukin-8/metabolism , Adult , Animals , Animals, Newborn , Chemokines/metabolism , Enzyme-Linked Immunosorbent Assay , Humans , Infant, Newborn , Inflammation , Monocytes/metabolism , Neutrophils/metabolism , Protein Isoforms , Swine
4.
J Biol Chem ; 284(9): 5945-55, 2009 Feb 27.
Article in English | MEDLINE | ID: mdl-19117939

ABSTRACT

CXC chemokines with a glutamate-leucine-arginine (ELR) tripeptide motif (ELR(+) CXC chemokines) play an important role in leukocyte trafficking into the tissues. For reasons that are not well elucidated, circulating leukocytes are recruited into the tissues mainly in small vessels such as capillaries and venules. Because ELR(+) CXC chemokines are important mediators of endothelial-leukocyte interaction, we compared chemokine expression by microvascular and aortic endothelium to investigate whether differences in chemokine expression by various endothelial types could, at least partially, explain the microvascular localization of endothelial-leukocyte interaction. Both in vitro and in vivo models indicate that ELR(+) CXC chemokine expression is higher in microvascular endothelium than in aortic endothelial cells. These differences can be explained on the basis of the preferential activation of endothelial chemokine production by low intensity shear stress. Low shear activated endothelial ELR(+) CXC chemokine production via cell surface heparan sulfates, beta(3)-integrins, focal adhesion kinase, the mitogen-activated protein kinase p38beta, mitogen- and stress-associated protein kinase-1, and the transcription factor.


Subject(s)
Chemokines, CXC/metabolism , Endothelium, Vascular/metabolism , Focal Adhesion Protein-Tyrosine Kinases/metabolism , NF-kappa B/metabolism , Stress, Mechanical , p38 Mitogen-Activated Protein Kinases/metabolism , Animals , Aorta/cytology , Aorta/metabolism , Blotting, Western , Electrophoretic Mobility Shift Assay , Endothelium, Vascular/cytology , Heparitin Sulfate/metabolism , Humans , Integrin beta Chains/metabolism , Luciferases/metabolism , Microvessels/physiology , NF-kappa B/genetics , Phosphatidylinositol 3-Kinases/metabolism , Plasmids , RNA Interference , Rats , Ribosomal Protein S6 Kinases, 90-kDa/metabolism , Signal Transduction , Swine , rho-Associated Kinases/metabolism
5.
J Investig Dermatol Symp Proc ; 12(1): 22-5, 2007 May.
Article in English | MEDLINE | ID: mdl-17502865

ABSTRACT

Tumor necrosis factor (TNF) plays a major role in the initial and long-term control of tuberculosis. The mechanisms by which this cytokine contributes to the control of Mycobacterium tuberculosis infection are numerous and therefore difficult to dissect. TNF is important in macrophage activation as well as cell recruitment to the site of infection. It is the primary signal important in granuloma formation, as neutralization of this cytokine leads to lack of control of initial or chronic infection, and loss of granuloma structure. In humans treated with TNF-neutralizing drugs, an increased susceptibility to tuberculosis, as well as other infectious diseases, is observed. We are using animal models to understand how TNF neutralization by these drugs can lead to reactivation of tuberculosis.


Subject(s)
Tuberculosis/immunology , Tumor Necrosis Factor-alpha/physiology , Animals , Antibodies, Monoclonal/adverse effects , Chemokines/physiology , Disease Models, Animal , Granuloma/etiology , Granuloma/immunology , Humans , Macaca fascicularis , Mice , Neutralization Tests , Tuberculosis/etiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors
6.
J Immunol Methods ; 270(1): 37-51, 2002 Dec 01.
Article in English | MEDLINE | ID: mdl-12379337

ABSTRACT

Interleukin-8 (IL-8) plays a central role in neutrophil chemotaxis and exerts a wide range of effects on various cells, ranging from tumor angiogenesis to impairment of neuronal signaling. Two main forms of IL-8 exist, one containing 77 amino acids (Ala-IL-8(77)) and a second containing 72 amino acids (Ser-IL-8(72)), which comprise more than 90% of IL-8 protein in cell cultures. IL-8(77) was reported to be produced predominantly by endothelial cells and is known as "endothelial" IL-8. IL-8(72) predominates in monocyte cultures and is known as "leukocyte" IL-8. While both forms have equal chemotactic activity in vivo, recent data suggest that their biological activities might be different. Here we describe the generation of a mouse monoclonal antibody (mAb) specific for IL-8(77) and the development of a corresponding immunoassay. Various immunization protocols were investigated. Immunization with conjugates of a peptide from the N-terminus of IL-8(77) (NTP(77)) resulted in the production of an IgG1 mAb (N11) that recognizes human IL-8(77) and neutralizes its chemotactic activity. A sensitive ELISA specific for IL-8(77) was developed using N11 for capture and a biotinylated mAb to IL-8(72) for detection. Using this immunoassay it was shown that the only form of IL-8 secreted in cell culture was IL-8(77) and that the IL-8(72) present was the result of proteolysis of IL-8(77). IL-8(77) was detected in plasma and cerebrospinal fluid (CSF) from patients with sepsis and meningitis.


Subject(s)
Antibodies, Monoclonal/immunology , Enzyme-Linked Immunosorbent Assay/methods , Interleukin-8/analysis , Alanine , Animals , Antibodies, Monoclonal/biosynthesis , Antibody Specificity , Cell Line , Chemotaxis , Female , Humans , Immunoblotting/methods , Immunoglobulin G , Interleukin-8/blood , Interleukin-8/cerebrospinal fluid , Interleukin-8/immunology , Mice , Mice, Inbred BALB C , Neutralization Tests , Peptides/immunology , Recombinant Fusion Proteins/immunology , Staining and Labeling/methods
7.
Blood ; 100(7): 2668-71, 2002 Oct 01.
Article in English | MEDLINE | ID: mdl-12239185

ABSTRACT

CXC chemokines play a central role in regulation of neutrophil activation and chemotaxis. Because the chemotactic responses of neutrophils are impaired after phagocytosis, we explored the effect of phagocytic stimuli on the expression of interleukin-8 (IL-8) receptors, CXCR1 and CXCR2, in human neutrophils. After phagocytosis of opsonized yeast, the expression of CXCR1 and CXCR2 was substantially down-regulated and was accompanied by reduced Ca(++) responses to corresponding ligands, IL-8 and neutrophil-activating peptide-2 (NAP-2). The levels of CXCR1 and CXCR2 mRNA were constant during phagocytic stimulation of neutrophils. Confocal microscopy revealed that CXCR reduction was not via internalization. Metalloproteinase inhibitor, 1,10-phenantroline, prevented the reduction of CXCRs induced by phagocytosis, indicating that proteolytic degradation may be responsible for down-regulation. These observations suggest that down-regulation of CXCR expression may substantially reduce the responsiveness of phagocytosing neutrophils to CXC chemokines.


Subject(s)
Down-Regulation , Neutrophils/immunology , Phagocytosis/physiology , Receptors, Interleukin-8A/genetics , Receptors, Interleukin-8B/genetics , Calcium/blood , Chemotaxis, Leukocyte/immunology , Cytosol/physiology , Flow Cytometry , Humans , In Vitro Techniques , Microscopy, Confocal , Neutrophils/cytology , Neutrophils/microbiology , Saccharomyces cerevisiae/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...